Company Overview
Sangamo Therapeutics, Inc. operates as a clinical-stage genomic medicine company dedicated to translating scientific discoveries into medicines designed to transform the lives of patients and families afflicted with serious diseases within the United States. The company functions within the Healthcare sector and specifically within the Biotechnology industry, positioning itself to address unmet medical needs through specialized gene therapy product candidates such as ST-920. As of the latest reporting period, the organization employs a workforce of 183 individuals and holds a market capitalization of $130.65M, while generating annual revenue of $32.88M over the trailing twelve-month period. These financial metrics indicate that Sangamo is a smaller-cap entity operating with limited revenue relative to its valuation, suggesting a company that relies heavily on future clinical development milestones and capital raising activities rather than established commercial cash flows to sustain its operations and fund its research and development efforts.
Financial Health
The company reported revenue of $32.88M for the trailing twelve months, yet this top-line figure is offset by a net income loss of $-108,909,000 and an EBITDA of $-104,683,000. The substantial gap between the $32.88M revenue and the $-108.9M net loss reveals a highly aggressive cost structure where operating expenses significantly exceed all sources of income, a condition typical of clinical-stage biotechnology firms investing heavily in trial execution. Free cash flow stands at $-38,798,752, indicating that the company is burning cash at a rapid rate, which severely limits its financial flexibility and necessitates continuous access to external capital markets or existing cash reserves to fund operations. The company's margin profile is stark, featuring a gross margin of -219.1%, an operating margin of -6119.3%, and a profit margin of 0.0%, all of which reflect the intense burn rate inherent in the early phases of drug development before any commercial product generates profitability. Regarding liquidity, Sangamo holds $29.62M in cash against $25.42M in debt, resulting in a debt-to-equity ratio of 407.24, which characterizes a highly leveraged balance sheet given the company's negative equity position. The current ratio is recorded at 0.88, indicating that the company's current assets are insufficient to cover its current liabilities without relying on asset sales or new financing. Furthermore, the return on equity is -480.0% and the return on assets is -68.1%, metrics that demonstrate management has not yet generated positive returns on the capital invested in the business, reflecting the speculative nature of the investment at this stage of development.
Valuation Assessment
Sangamo Therapeutics presents a complex valuation picture with a trailing P/E ratio of N/A due to its losses, while the forward P/E is listed at -1.88, implying that the market does not expect immediate earnings normalization or profitability in the near term. The price-to-book ratio is exceptionally high at 18.50, indicating that the market values the company at a significant premium over its tangible book value, likely driven by the potential value of its intellectual property and clinical pipeline rather than current assets. Alternative valuation metrics such as the price-to-sales ratio of 3.97 and an EV/EBITDA of -1.09 suggest that the stock is priced based on revenue multiples typical of growth biotech firms, despite the negative earnings multiple, highlighting the disconnect between current profitability and market pricing. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $0.32 and a 52-week high of $0.93. Assuming the current market price approximates the midpoint of the recent trading range for illustrative context, the stock trades within the lower to middle portion of this range, reflecting the high-risk nature of the asset. The beta of 1.32 indicates that the stock is 32% more volatile than the broader market, suggesting that price movements will be amplified during periods of market stress or sector-specific news.
Growth & Income
The company's growth profile is defined by a revenue decline of -98.8% year-over-year, while earnings growth is listed as N/A due to the company's ongoing losses. This contraction in revenue suggests a potential restructuring of sales channels, a pause in commercialization, or a shift in reporting periods, and since earnings are negative, the traditional comparison of earnings growth versus revenue growth is not applicable in the conventional sense. As a non-dividend payer, the company does not distribute a dividend yield or payout ratio, which is consistent with its stage of development where earnings are reinvested back into the business to fund research, development, and clinical trials rather than being returned to shareholders. The overall growth and income profile of Sangamo Therapeutics is characterized by negative revenue momentum and an absence of income generation, positioning the investment entirely on the potential for future value creation through the successful commercialization of its product candidates rather than current financial performance.